IMI 2 Call 8 'Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks' now open

Call description

The Innovative Medicines Initiative (IMI) has launched a new, open Call for proposals in the area of Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks.

Call ID:  H2020-JTI-IMI2-2015-08-single-stage

Action Type:

Research and Innovation Action


  • Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks

Please read the IMI2 Call 8 Topic Text  for full details of the topic, incuding the budget and the General Conditions for the Call for proposals.

Please note that entering, revising and submitting short proposals for this call can only be done through the IMI SOFIA software tool.

Indicative budget

The indicative financial contribution from the IMI2 JU for the entire period of 2 years will be a maximum of EUR 70 000 000.

The entire budget for this call will be available as from the first cut-off date. Three months prior to each subsequent cut-off date, the amount of the remaining budget will be published on the IMI website.

Key dates

Publication date: 18 December 2015

This call for proposals is continuously open for a period of two years with the following cut-off dates for submission of proposals:

16 March 2016, 15 September 2016, 16 March 2017, 14 September 2017, 15 March 2018.

General information

This Call, the second under the Ebola+ programme, provides an opportunity to capture emerging scientific advances and to progress those rapidly into healthcare interventions. As such, the key deliverables of projects funded under the Ebola+ programme must be outputs that will increase our preparedness to react to future outbreaks of Ebola and other filoviral haemorrhagic fevers.

Key deliverables could include (but are not limited to):

  • the progression of a novel vaccine candidate, diagnostic or treatment up to a stage ready for testing in an outbreak setting;
  • the development of tools to help with pre-clinical and clinical development of vaccine candidates and treatments;
  • the development and/or validation of a novel diagnostic test that is sufficiently sensitive, rapid, user-friendly, cheap, and usable in resource-limited settings;
  • the development of novel strategies to improve the stability of vaccines against Ebola and other filoviral infections during transport and storage, e.g. which would allow storage at 8°C or ambient temperatures for prolonged durations;
  • the development of novel manufacturing and delivery strategies;
  • the development of learning and strategies for optimal deployment and adherence to vaccination programmes;
  • the facilitation of the exploitation of recent advances in our understanding of Ebola and other filoviral infections and the acceleration of their development into healthcare interventions.

IMI encourages small and medium-sized enterprises (SMEs), mid-sized companies, patients’ organisations, regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and apply to participate in the new IMI projects.


For the full call information and application forms please proceed to the call website.

Source: IMI